The European Society of Medical Oncology (ESMO) clinical practice guidelines  are intended to provide oncology professionals with a set of recommendations for the best standards of cancer care, based on the findings of evidence-based medicine. The guidelines include the following recommendations for the use of sFLC measurements:
sFLC analysis is recommended in the initial diagnostic work-up of patients with suspected MM, and is included as a biomarker of malignancy in the updated criteria for the diagnosis of MM, as defined by the IMWG (Section 25.2.1).
Response evaluation and follow-up
IMWG response criteria, which include sFLC analysis, should be used for response evaluation (Section 25.3.5). Outside the context of a clinical trial, it is recommended that serum and urine electrophoresis and/or sFLC determination should be carried out every 2 - 3 months and that sFLC measurement may contribute to the detection of light chain escape.